Pacira BioSciences, Inc. (PCRX)

NMS – Real vaqt narxi. Valyuta: USD

23.82

-0.56 (-2.32%)

Bozor ochiq: Aug 12, 2026, 3:09 PM EDT

24.38

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 5:19 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Pacira BioSciences, Inc. (PCRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videolar

No Data

Press-relizlar

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Search stocks

Pacira BioSciences, Inc. (PCRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videolar

No Data

Press-relizlar

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results